CD22 / Luciferase - CHO Recombinant Cell Line

Catalog #

79715

$9,400 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771) and the firefly luciferase. Surface expression of CD22 was confirmed by flow cytometry.

This product has been cited 2 times.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

Siglec-2

●

Product Data Gallery

Expression of CD22 validated by flow cytometry

Luciferase activity of CD22/Luciferase CHO recombinant cells

Product Info

Storage and Usage

Citations2

Host Cell Line

CHO K1 cell line, Chinese Hamster Ovary

Supplied As

Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.

Materials Required But Not Supplied

• Thaw Medium 3 (BPS Bioscience, #60184)

• Growth Medium 3A (BPS Bioscience, #60188)

• 96-well tissue culture-treated white clear-bottom assay plate

• ONE-Step luciferase assay system (BPS Bioscience, #60690) or other luciferase reagent for measuring firefly luciferase activity

• Luminometer

UniProt #

P20273

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Background

CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body’s B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.

References

1. Poe J, et al. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012 Aug; 33(8):413-420.

2. Dorner T, et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews. 2015 14:1079-1086.

3. Wei G., et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. Journal of Hematology and Oncology. 2017 10:1-13.

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 3 (BPS Bioscience, #60186): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3A (BPS Bioscience, #60188): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml G418 and 500 μg/ml of Hygromycin B to ensure recombinant expression.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid multiple freeze thaw/cycles

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

CD22 / Luciferase - CHO Recombinant Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY